INTRODUCTION
Recognition that neuroactive compounds derived from the intestinal lumen can permeate the mucosa (healthy or diseased), cross the blood±brain barrier and cause psychiatric, cognitive and behavioural disturbances is not new; indeed, this axis is critical in oral medication of psychopathology. There is a growing awareness, particularly within the ®eld of childhood developmental disorders, that, in a proportion of affected children, gut±brain interactions may contribute to abnormal neural development and the subsequent expression of aberrant behaviours. Dif®culties in accepting the biological plausibility of such a model, particularly when attention has been focused upon primary pathogenetic mechanisms operating within the central nervous system, may re¯ect, in part, a perceived lack of an analogous gut±brain interaction in either human or experimental models of encephalopathy. Among gastroenterologists and hepatologists, however, the evidence for such a mechanism is readily apparent. It may help advance the argument by seeking analogy with circumstances in which there is clear evidence for an in¯uence of the gut upon the normal brain.
SUMMARY
There is growing awareness that primary gastrointestinal pathology may play an important role in the inception and clinical expression of some childhood developmental disorders, including autism. In addition to frequent gastrointestinal symptoms, children with autism often manifest complex biochemical and immunological abnormalities. The gut±brain axis is central to certain encephalopathies of extra-cranial origin, hepatic encephalopathy being the best characterized.
Commonalities in the clinical characteristics of hepatic encephalopathy and a form of autism associated with developmental regression in an apparently previously normal child, accompanied by immune-mediated gastrointestinal pathology, have led to the proposal that there may be analogous mechanisms of toxic encephalopathy in patients with liver failure and some children with autism. Aberrations in opioid biochemistry are common to these two conditions, and there is evidence that opioid peptides may mediate certain aspects of the respective syndromes. The generation of plausible and testable hypotheses in this area may help to identify new treatment options in encephalopathies of extra-cranial origin.
Therapeutic targets for this autistic phenotype may include: modi®cation of diet and entero-colonic microbial milieu in order to reduce toxin substrates, improve nutritional status and modify mucosal immunity; anti-in¯ammatory/immunomodulatory therapy; and speci®c treatment of dysmotility, focusing, for example, on the pharmacology of local opioid activity in the gut.
HEPATIC ENCEPHALOPATHY
Hepatic encephalopathyÐa variable impairment of cerebral functioning in patients with acute or chronic liver diseaseÐis the result of multiple biochemical in¯uences upon central neurotransmitter systems. In addition to the neurotoxic effects of ammonia, derangements in the c-aminobutyric acid-ergic (GABA-ergic), serotoninergic and dopaminergic 1, 2 systems are evident (reviewed by Albrecht & Jones 3 and Butterworth 4 ). It may be more than just coincidence that changes in some of these neurotransmitter systems have also been described in autism. 5±7 Central to changes in the activity of these various systems in hepatic encephalopathy is a failure of the diseased liver to metabolize and eliminate toxic compounds derived from the gut. Hepatic encephalopathy may also be induced by porta-systemic shunting (re-routing the venous drainage of the gut to bypass the liver and enter the systemic circulation directly) for the amelioration of portal hypertension. Precipitants of hepatic encephalopathy in patients with liver disease include a high entero-luminal protein load, constipation and sepsis. 3, 4 The clinical management of hepatic encephalopathy includes restriction of dietary protein, prompt treatment of constipation and antibiotic therapy directed against luminal colonic bacteria. As such, hepatic encephalopathy represents a prototypic afferent gut± brain interaction that may provide insight into other encephalopathic states that have been linked to extracranial pathology. Are there circumstances in which primary gut pathology might also adversely affect the central nervous system?
ENTERO-COLONIC ENCEPHALOPATHY
Untreated coeliac diseaseÐan aberrant immune response to dietary gliadinÐis associated with intestinal mucosal in¯ammation, increased intestinal permeability, 8 increased absorption and urinary excretion of neuroactive dietary peptides, 9 and in some autistic and psychotic behaviours 10, 11 and neurological complications. 12, 13 Where coeliac disease is clinically silent due to a lack of gastrointestinal symptoms, a careful history often reveals that, in many such cases, there is lowintensity comorbid illness 14 associated with decreased psychophysical well-being that includes, in children, behavioural disturbances with a tendency to depression, irritability and impaired school performance. Fabiani et al. described an increase in weight and height velocity, appetite, mood amelioration and an improvement in physical and school performance, in adolescents whose coeliac disease was apparently asymptomatic at diagnosis, once they began following a gluten-free diet. 15 The precise mechanism(s) of behavioural and neurological sequelae in coeliac disease has not been established, although toxicity from the gut 9 and autoimmunity 16 are pathogenetic forerunners.
D-Lactic acidosis, a complication of acid-tolerant bacterial overgrowth in patients with short bowel syndrome and those undergoing intestinal bypass surgery for obesity, is associated with a range of psychiatric and neurological sequelae. 17 Patients may present with altered mental state, aggression, stupor, ataxia and asterixis; these symptoms respond rapidly to oral antibiotic treatment. Encephalopathy is a recognized presenting feature of intestinal intussusception in infants, 18±20 and, intriguingly, may be reversible with naloxone. 18 Constipation alone may precipitate confusional states in the elderly.
THE GUT IN AUTISM: CLINICAL PRESENTATION AND SUBCLINICAL DISEASE
Recently, there has been growing interest in the role of the gut in developmental disorders, principally autism. Gastrointestinal symptoms are common in children with developmental disorders, a fact that was recognized by some of the earliest commentators on pathobiological mechanisms in autism; in 1986, Dohan was reported to have written:`K. Soddy (University College Hospital, London) wrote me that he noted that recurrent gastrointestinal upsets were a constant feature of autistic children and that, among other symptoms, the deteriorating autistic child often has acute diarrhoea.' 21, 22 These observations feature prominently in parental accounts, but have been largely ignored in the autism literature. In a systematic analysis of an unselected population of 385 children on the autistic spectrum, clinically signi®cant gastrointestinal symptoms occurred in 46%, compared with 10% of 97 developmentally normal paediatric controls (odds ratio, 7.4; con®dence interval, 3.60±15.65; P < 0.0001). 23 We have investigated gastrointestinal symptoms in over 150 autistic children and have reported our early experience. 24, 25 In this cohort of children, a period of initial normal development was followed by developmental regression and loss of acquired skills, consistent with a subacute encephalopathy, sometimes presenting over a period of weeks to a few months. Long-standing intestinal symptoms, including pain, oesophageal re¯ux, diarrhoea, chronic constipation with over¯ow and provocation of both gastrointestinal and behavioural symptoms by certain foods, are typical of this group of children and have been described by others. 23, 26 Frequently, careful attention needs to be paid to the history in order to adduce these symptoms; an autistic child in pain who is unable to communicate normally may be distressed, aggressive and self-injurious; our early ®ndings that bowel clearance often abrogates these behavioural symptoms is a clue to their likely intestinal origin.
Intestinal permeability, as measured by urinary excretion of metabolically inert sugars after oral dosing, is a surrogate marker of mucosal integrity and is elevated in the presence of intestinal in¯ammation, as in Crohn's disease 27 and coeliac disease. 8 D'Eufemia et al. reported that approximately half of a cohort of autistic children without gastrointestinal symptoms had raised intestinal permeability. 28 Increased intestinal permeability in children with autism has also been reported by Horvath et al.; 29 we are currently attempting to reconcile the dif®culties associated with obtaining a standard urine collection in affected children and, to date, have encountered shortcomings in the estimation of permeability on spot urine samples (A. J. Wake®eld, unpublished observations, 2001 ). The precise role or frequency of increased paracellular permeability in children with autism is not known. In addition, it is not clear to what extent data derived from changes in the permeability of the epithelium to inert sugars are relevant to the absorption of neuropeptides, as discussed below. Nonetheless, D'Eufemia's detection of aberrant intestinal permeability in asymptomatic autistic children indicates that reliance upon symptomatology will substantially underestimate the proportion of autistic individuals with possible gastrointestinal pathology. The situation may mirror the subclinical`iceberg' effect that is evident for coeliac disease. Any underestimate in autism will be compounded by the combination of a raised pain threshold that may be present in affected children 30 and by their restricted ability to communicate symptoms. However, for many, the perception remains that intestinal symptoms are to be expected in children with developmental disorders, re¯ecting effect rather than primary gastrointestinal dysfunction. It is essential, as a ®rst step, to ask whether these symptoms re¯ect underlying visceral pathology. The identi®cation of increased intestinal permeability in a patient is not a diagnostic end-point, but indicates the need for further detailed investigation. As a corollary to changes in intestinal permeability, there is compelling evidence that many children with autism and gut symptoms have demonstrable organic pathology of the gastrointestinal tract. We have recently described a characteristic pattern of intestinal pathologyÐileoco-lonic lymphoid nodular hyperplasia and enterocolitisÐin a cohort of autistic children. The endoscopic and histopathological characteristics of this condition have been reported in detail elsewhere. 24, 25 A comparison of the mucosal lesion in both the colon and small intestine with appropriate controls reveals a pathology that may be distinct from established forms of mucosal in¯ammation; brie¯y, the colonic lesion consists of a mucosal in®ltrate of cd T cells and CD8 + T cells, signi®cantly in excess of that seen in either normal or disease control groups. 31 Crypt cell proliferation is substantially enhanced and the epithelial basement membrane is thicker than in either normal or disease control groups. Neutrophil and eosinophil in®ltration of the mucosa is evident. The absence on colonic epithelium of human leucocyte antigen, HLA-DR, in autistic children suggests a T-helper-2 (T H 2)-dominated immune response. 31, 32 Studies of the corresponding small intestinal lesion also indicate a distinct cell-mediated immunopathology in which immune-mediated epithelial damage is predominant, serum immunoglobulin G colocalizes with complement (C1q) at the epithelial basolateral membrane and epithelial proliferation is grossly increased. 33 This is not seen in either healthy children or those with cerebral palsy. The intestinal changes are consistent with an autoimmune pathology and, in view of the increasing evidence for gut epithelial dysfunction in autism, are indicative of a speci®c and possibly important lesion. Bellanti and colleagues have presented preliminary evidence of similar ®ndings in some children with attention de®cit hyperactivity disorder, 34 suggesting that gastrointestinal pathology may be relevant to a broader spectrum of childhood developmental/behavioural disorders. Horvath et al. have reported their ®ndings in the upper gastrointestinal tract in 36 autistic children, whose symptoms included chronic diarrhoea, gaseousness, abdominal discomfort and distension. 26 They detected grade I±II re¯ux oesophagitis in 25 (69%), chronic gastritis in 15 (42%) and chronic duodenitis with associated Paneth cell hyperplasia in 24 (67%). Digestive enzyme activity was low in 21 (58%) and pancreatico-biliary¯uid output in response to intravenous secretin was raised in 27 (75%). Subsequent to Horvath et al.'s early report, we have included upper gastrointestinal endoscopy in our own routine assessment of affected children and have obtained similar ®ndings.
In summary, within the autistic spectrum, there is a substantial group of children presenting with what may be a primary, immune-mediated, intestinal pathology. The constellation of developmental disorder and gastrointestinal pathology (provisionally termed autistic enterocolitis) combines the paradoxical elements of a motility disorder (oesophageal re¯ux plus constipation with spurious diarrhoea) and entero-colonic mucosal in¯ammation (a feature more commonly associated with frank diarrhoea). Understanding the neurochemical and immune basis of any gut±brain interaction in autistic enterocolitis may help to resolve this paradox and develop rational therapeutic approaches.
During the course of the clinical assessment and management of these children, we have been impressed by the symptomatic improvement in their behaviour and general well-being following bowel clearance prior to colonoscopy, treatment of intestinal in¯ammation with 5-aminosalicylate-based compounds or a polymeric diet, 35 relief of chronic constipation and, in particular, the elimination of certain proteins (casein and/or gluten) from the diet. Bolte has proposed a role for intestinal clostridial dysbiosis in autism, speci®cally via neurotoxic encephalopathy. 36 In seeking to test this hypothesis, Sandler et al. noted objective cognitive improvement in autistic children in an open-label study of oral vancomycin, 37 an antibiotic that exhibits minimal systemic absorption. Children regressed following the cessation of therapy, suggesting that any colonic dysbiosis and associated toxic sequelae were likely to be secondary to the underlying intestinal pathology rather than the primary problem. It seems likely that the evidently dysfunctional mucosal immune system in these children creates an environment that favours anaerobic dysbiosis which is ameliorated only temporarily by vancomycin. The ®ndings of Bolte and colleagues, although observed in an open-label study, were largely unexpected. They are, in addition, reminiscent of certain aspects of the clinical course of hepatic encephalopathy, where oral, non-absorbable antibiotic treatment is a ®rst-line therapy. Is it possible that an analogous interaction might be operating in a subset of autistic children? If so, clues to any biochemical basis for such interactions in autism might be identi®able in syndromes such as hepatic encephalopathy.
AUTISM AND OPIOID EXCESS
It has been proposed that some forms of autism may arise from the toxic effects of intestinal products on the developing brain. Kalat, 38 Dohan, 39 Panksepp, 40 Reichelt et al., 41 Shattock et al. 5 and Sun et al. 42, 43 have proposed that autism may be caused by inappropriate central activity of dietary-derived opioid peptides (exorphins) from the gut. These include gliadmorphine and b-caseomorphine from the substrates wheat gliadin and bovine casein, respectively. Under normal circumstances, these abundant dietary opioids are digested by brush border peptidases, such as dipeptidyl peptidase IV.
Intestinal in¯ammation is associated with increased epithelial permeability that might facilitate the absorption of dietary peptides, as in coeliac disease, 9 leading to systemic opioid excess. Intestinal in¯ammation is also associated with impaired digestive enzyme activity, as shown for hydrolase activity in autistic children by Horvath et al. 26 and dipeptidyl peptidase IV in coeliac disease. 44 Diminished peptide hydrolysis and an increased luminal opioid load may contribute to any systemic excess. Once exorphins from the intestinal lumen become systemic, the potential exists for them to exert direct effects within the central nervous system, and also to act indirectly by in¯uencing the activity or breakdown of endogenous opioids (endorphins) by inhibition of tissue endopeptidases.
45±49
In our cohort of autistic children, opioid-mediated intestinal dysmotility would provide a rational explanation for the clinical paradox of an enterocolitis associated with chronic constipation and re¯ux oesophagitis. Opioids exert potent effects upon motor and secretory activity in the gastrointestinal tract, increasing the gastric emptying time and inducing changes in colonic myo-electrical activity, with concomitant spasm, pain and constipation. 50 In the central nervous system, exposure to opioid excess during a critical phase of early cerebral development may not only adversely in¯uence this development, but also increase the long-term susceptibility to systemic opioids, whether exogenous or endogenous in origin. It has been demonstrated that, in rodents, perinatal exposure to an opioid excess leads to a permanent increase in the active transport of systemic opioid across the blood±brain barrier. 51 What, then, are the possible consequences of aberrant opioid activity for the rapidly transitional infant nervous system.
OPIOIDS AND DEVELOPMENT OF THE CENTRAL NERVOUS SYSTEM
There is clear evidence from model systems that, in the developing brain, endogenous opioids and opioid receptors play a central role in neuro-ontogeny.
52±58
Moreover, studies of prenatal drug abuse con®rm that exogenous opioids can permanently perturb the developing brain, leaving affected children with associated de®ciencies, including problems with learning and interpersonal relations. 59 In an extensive and elegant series of studies, Zagon and McLaughlin con®rmed that opioids and their receptors interact during brain development, and that opioid systems play an integral role in cellular proliferation, migration and differentiation within the developing central nervous system. 52±58 Factors that were crucial in de®ning the speci®c patterns of aberrant neural development in rodents included the timing of experimental opioid perturbation in relation to the stage of central nervous system development; 52, 54, 57, 58 the numbers of prenatally derived neural elements, such as cerebellar Purkinje cells, were not in¯uenced by postnatal opioid antagonism, whereas the development and growth of dendritic spines in these same cellsÐlargely postnatal eventsÐwere altered profoundly. This observation may have considerable importance for our understanding of the timing (and possibly identi®cation) of aetiological events and the associated autistic phenotype, as indicated by Courchesne. 60, 61 Post-mortem studies of autistic brains, although limited by small numbers, have revealed that, consistent with Zagon and McLaughlin's observations, abnormalities in cell number (particularly cerebellar Purkinje cells) and dendritic arborization (particularly within the hippocampus) were two prominent characteristics that distinguished those with autism from neurologically normal controls. 62±64 It was concluded that brains from those with early infantile (Kanner) autism 65 and from low functioning autists with`mental retardation' 65, 66 exhibited changes that were consistent with an aetiological factor operating in utero. It would be interesting to compare the morphology in these historical cohorts with that of autistic patients who undergo regression following a period of normal development.
In the studies of Zagon and McLaughlin, the effects of opioid antagonists on central nervous system morphogenesis and function were dose dependent, and varied according to the kinetics of delivery of the opioid antagonist (continuous or intermittent). In turn, according to the timing, dose and mode of administration of opioid antagonist, speci®c patterns of aberrant neural development were re¯ected in characteristic and measurable changes in behavioural ontogeny. 52 Against this background, there are (in addition to the clear consequences of opioid abuse) clinical and experimental data suggesting that aberrant patterns of neural development and behaviour, including autism, may develop in association with exposure of the brain to opioid excess. Evidence for such an association includes: the detection of bovine b-caseomorphine-7 (exclusively of dietary origin) in the urine, blood and cerebrospinal uid of patients with psychoses, including autism; 5, 67, 68 the demonstration that, in an animal model, systemically administered b-caseomorphine-7 (or an active peptide derivative thereof ) crosses the blood±brain barrier, binds to and induces early activation gene-like (C-Fos) reactivity in areas of the brain that are implicated in autism, 42 and that this induction is attenuated or blocked in a region-speci®c manner by the pre-administration of the opioid antagonist naloxone; the demonstration of profound dose-dependent behavioural changes in the same animal model following peripheral administration of b-caseomorphine-7 (also attenuated or prevented by naloxone pre-treatment); 43 and the reported therapeutic bene®t of dietary exclusion of the opioid substrates in autistic children. 69±75 Trials of the oral opioid antagonist, naltrexone, in autism have identi®ed improvements, particularly in behavioural domains such as selfinjury. 76±81 Nonetheless, results have been mixed and ultimately inconclusive. When interpreting these studies, it is important to take into account the narrow range of therapeutic ef®cacy for naltrexone as an opioid antagonist, and its U-shaped dose±response curve that would predict a bene®cial effect at low doses and either no effect or a paradoxical aggravation of symptoms at higher doses. Unfortunately, few studies appear to have considered the relevant pharmacodynamics of opioid antagonists in the design of such trials.
More recently, using electrospray mass spectroscopy to examine the urine of autistic children, Friedman and colleagues have identi®ed, in addition to caseomorphine, a number of interesting and potentially relevant molecules. 82 These include deltorphine, a morphine modulating peptide, and dermorphine; the latter moleculeÐa potent hallucinogenÐis intriguing as it contains a D-alanine in the second position from the C-terminal. In such a con®guration, dermorphine would be resistant to mammalian peptidases. In nature, it is found in the skin of non-captive South American poison dart frogs, where it may be a microbial product, providing possible clues to its origin in the urine of autistic children.
OPIOID PEPTIDES AND HEPATIC ENCEPHALOPATHY
Of speci®c interest within the context of the current review is the increasing awareness of a role for opioid peptides in mediating the central effects of hepatic encephalopathy. Plasma levels of the endorphins, methionine-enkephalin and leucine-enkephalin, are increased in patients with cirrhosis, 83 and methionineenkephalin is elevated in patients with acute liver disease. 84 Changes in central opioidergic activity have been reported in different experimental models of fulminant hepatic failure 85, 86 and porta-caval shunting; 87 the amelioration of symptoms with opioid antagonists is of particular interest. 85, 86 A prerequisite for the participation of opioids, particularly exorphins, in the pathogenesis of central nervous system changes associated with hepatic encephalopathy and autistic enterocolitis would be evidence of altered opioid activity in the cerebrospinal¯uid. Changes in cerebrospinal¯uid endorphin and/or exorphin activity might be anticipated in view of the potential for exorphins, such as bovine b-caseomorphine, both to enter the central nervous system 88, 89 and in¯uence cerebrospinal¯uid endorphin levels through inhibitory effects on tissue peptidase activity.
45±49
In hepatic encephalopathy, alterations in cerebrospinal uid endorphin levels are well established. Yurdaydin et al. showed that plasma and cerebrospinal¯uid levels of endogenous methionine-enkephalin were signi®cantly greater in patients with hepatic encephalopathy compared with both healthy controls and patients with lumbar back pain. 90 As far as we are aware, exorphins of dietary origin have not been sought in hepatic encephalopathy, although the bene®cial effects of dietary protein restriction, in addition to reducing substrates for ammonia synthesis, provide an empirical rationale for looking. The exorphin, bovine b-caseomorphine, which has been associated most consistently with autism, can cross the human blood±brain barrier; Nyberg et al. have identi®ed dietary-derived bovine b-caseomorphine-8 in the cerebrospinal¯uid of otherwise healthy lactating women, 89 and linked excessive levels to postpartum psychosis. 67 Molecular speci®city in support of this claim requires con®rmation by mass spectroscopy. In addition, autism is associated with changes in cerebrospinal¯uid endorphin levels; Gillberg et al. identi®ed high levels of endorphin fraction II (as de®ned by receptor-based assays) in the cerebrospinal¯uid of children with autism, which also correlated with a reduced sensitivity to pain, a common ®nding in these children. 91 Gillberg et al.'s study did not characterize the relevant opioid(s) further, although fraction II peptides that have been identi®ed in human cerebrospinal¯uid are mainly C-terminal elongated enkephalyl peptides, including methionine-enkephalinlysine 6 and methionine-enkephalin-arginine 6 -phenylalanine 7 , both of which derive from the common precursor proenkephalin. 92, 93 Within the central nervous system, opioids coexist with and modulate the effects of a wide variety of other neurotransmitter systems, including GABA-ergic, serotoninergic, dopaminergic and noradrenergic systems, which have been implicated in the pathogenesis of hepatic encephalopathy and autism. Sun et al.'s study of the pharmacological effects of b-caseomorphine-7 in rat brain showed the induction of gene activation in areas known to be either sources or components of dopaminergic, serotoninergic and GABA-ergic pathways. 42 The behavioural abnormalities noted in this rat model by the same authors following systemic opioid administration were consistent with overactivity of the dopaminergic system. 43 Sun et al. concluded that uptake of b-caseomorphine-7 by areas of brain pertinent to autism supports the hypothesis that dietary gluten and casein could be a cause of this condition, and is consistent with clinical improvement of autistic children placed on dietary exclusion of these substrates.
FURTHER CONSEQUENCES OF IMPAIRED DETOXIFICATION MECHANISMS
Experience with hepatic encephalopathy has demonstrated that the effects of liver dysfunction upon neurotransmitter biochemistry are complex, and that it is dif®cult to correlate derangements in any one system with the severity of the clinical syndrome. We should not expect it to be any less complex in autism if analogous mechanisms pertain. Once again, however, hepatic encephalopathy may provide some clues for the study of autism. For example, it is well documented that abnormalities of glutamate/glutamine metabolism are prominent in patients with hepatic encephalopathy 94 and autism, 7 including autistic children with intestinal mucosal immunopathology. 95 Compared with the former pathology, however, little has been done to progress our understanding of the signi®cance of these abnormalities in autism. Glutamate is an important central nervous system metabolite and a major excitatory neurotransmitter. Once released from the presynaptic nerve terminal, it causes an increase in sodium conduction at the postsynaptic membrane and neurone ®ring. Inactivation is mainly within the perisynaptic astrocyte where re-uptake is associated with the glial glutamate transporter-1 (GLT-1) system. 96 Metabolism includes transamination with oxaloacetic acid, decarboxylation (to GABA) and the addition of an ammonia group to form glutamineÐa reaction catalysed by glutamine synthetase. An additional source of central nervous system glutamate in hepatic encephalopathy is via ammonia, synthesized by colonic bacteria and the deamination of glutamine in the small intestine. Following passive diffusion across the mucosa, failure by the diseased liver to effect what should, under normal circumstances, be a high ®rst-pass clearance, leads to excessive ammonia levels in the brain. The consequence of sustained elevation of central nervous system glutamate concentrations in hepatic encephalopathy complicating chronic liver disease is a shift towards inhibitory neurotransmission.
3, 4 Impaired uptake of glutamate into nerve endings and astrocytes leads to excessive extra-synaptic accumulation that, in turn, is associated with the down-regulation of the glutamate receptor and decreased glutaminergic tone. In both hepatic encephalopathy and autism, a number of similarities have been described, including a decrease in the GLT-1 level in astrocytes, 96 an increase in systemic L-glutamic acid level and an associated decrease in glutamine, 3, 4 ®ndings that are apparent in children with autistic enterocolitis. 95 While the signi®cance of these changes remains to be fully elucidated, decreasing the substrate for glutamate synthesis, by reducing the availability, for example, of ammonia from the gut, is of therapeutic bene®t in hepatic encephalopathy. While, in children with autistic enterocolitis, it is the integrity of the intestinal mucosa rather than the liver that appears to be at fault, understanding any associated derangements in amino acid biochemistry might allow a similar rational therapeutic approach. Our understanding of autism might also bene®t from further insights provided by hepatic encephalopathy, including the observations of up-regulated benzodiazepine receptors and associated increases in the inhibitory neurotransmitter GABA. 97 Conversely, for understanding hepatic encephalopathy, the analysis of certain biochemical derangements that have been reported in autism, such as defective sulphoconjugation, may be a productive line of investigation. Sulphotransferase-mediated sulphation of phenolic amines is an important detoxi®cation system; Waring and colleagues have reported abnormal sulphate metabolism 98 with associated sulphate de®ciency in autistic children. 99 This may impair their ability to metabolize phenolic amines such as serotoninÐraised levels of which have been described in autistic children 100, 101 Ðpossibly contributing to neurological and behavioural symptoms. Impaired sulphation capacity may also contribute to abnormalities of the mucosal intercellular matrix and luminal mucins, which may be an important factor in epithelial dysfunction, as in in¯ammatory bowel disease. 102 
WINDOWS OF VULNERABILITY AND CLINICAL COURSE OF DISEASE
From a clinical perspective, it may be argued that hepatic encephalopathy, unless prolonged, is fully reversible, whereas autism is not. However, the extent to which hepatic encephalopathy is reversed depends entirely on the institution of appropriate therapy that may include liver transplantation. Predicting a similar therapeutic response in the relevant subset of children with autism would require a much better understanding of the associated biochemical derangements. For example, some children with autism may exhibit behavioural/developmental improvements when placed on a diet that excludes certain opioid substrates, but tend to plateau at a level that is still demonstrably autistic. As illustrated above, it is likely that, in the relevant subset of children with autism, in¯uential exogenous neurotoxins would probably consist of more than just casein-and gliadin-derived opioids and therefore the ameliorative effect of excluding these substrates would be only partial. Alternatively, although not exclusively, as opioid peptides are intimately involved in the regulation of neural ontogeny from an early stage, an opioid excess at a critical phase of cerebral development may produce enduring cognitive de®cits that are not fully corrected by subsequent dietary restriction. Logically, therefore, the window of vulnerability for sustaining permanent impairment or susceptibility might be a neurotoxic exposure, such as an opioid excess, during a time of critical neuronal development during the ®rst years of life. In affected children, it might be anticipated that the clinical manifestationsÐthe autistic phenotypeÐwill re¯ect the state of central nervous system development at the time of neurotoxic exposure, as evidenced by Zagon and McLaughlin's studies of the effect of opioid receptor blockade on neuro-ontogeny. 52±58 The recent apparent upsurge in regressive autism (a phenotype speci®cally addressed for the ®rst time in the new Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) revised criteria 103 ) possibly re¯ects an exposure that is delayed beyond the period of normal cerebral development that is accompanied by the acquisition of certain skills and behaviours. A narrow window of susceptibility for the induction of aberrant neural development may go some way to explaining why older children with alternative mucosal pathology, e.g. Crohn's disease and ulcerative colitis, the onset of which is unusual before 10 years of age, have not, until recently, been reported to be at excess risk of autistic spectrum disorders. It is interesting, however, that patients with these mucosal pathologies of later onset do manifest an excess of psychiatric and neurological problems 104 which, in Crohn's disease, may pre-date the onset of intestinal symptoms. 105 Intriguingly, Ericsson et al. have recently identi®ed a statistically signi®cant excess risk for autistic spectrum disorder in children with perianal/®stulizing Crohn's disease. 106 Might a delayed entero-colonic encephalopathy be operating in such patients?
ALTERNATIVE GUT±BRAIN ASSOCIATIONS
The merits of proposed alternative mechanisms of cerebral injury should be considered. Autoimmunity is one such mechanism, in which any concurrent gut and brain pathologies might operate either independently, or as part of a systemic autoimmune disorder. Immunological abnormalities appear to be common ®ndings in children with autism, 107±110 with increasing evidence for a signi®cant autoimmune contribution to disease pathogenesis, 111±113 particularly in those with enterocolitis. 31, 33 The mucosal lesion in the small and large intestine is consistent with an autoimmune pathology, and the presence, in some affected children, of antibodies to myelin basic protein, 111 neuro®lament protein 112 and cerebrovascular endothelium 113 suggests the possibility of cerebral damage due to an autoimmune response to structural components of the central nervous system. There are, however, several inconsistencies in this hypothesis that require explanation. In addition to being a likely grey matterÐrather than white matterÐdisorder, autism is not progressive. This is in contrast to other chronic immunopathologies associated with the presence of anti-myelin basic protein antibodies, such as multiple sclerosis. Imaging and histopathological studies do not support an in¯am-matory central nervous system pathology in autism. As part of our initial investigations, 24 we undertook cerebral magnetic resonance imaging, electroencephalography and biochemical analysis of cerebrospinal uid: none of these investigations indicated cerebral in¯ammation that would be consistent with an autoimmune process, although a more subtle lesion remains a possibility. Alternatively, the ®nding of a variety of autoantibodies in affected children suggests that, due to underlying immune aberrations, they may overproduce such antibodies, but their pathogenetic signi®cance, if any, has yet to be determined. Finally, it would be naive to consider opioid-mediated effects and autoimmunity independently, without reference to the fact that there may be substantial cross talk between the two. Opioid peptides and their receptors have been widely implicated in the regulation of certain immune responses, including lymphocyte apoptosis. 114 The in vivo activation of central and peripheral opioid receptors by, for example, b-endorphin or morphine leads to the suppression of cellular immune responses, including lymphocyte proliferation, natural killer cell activity, interleukin-2 and interferon-c production. 115 Conversely, the administration of opioid receptor antagonists in a murine model induces the stimulation of these same responses that is associated with a skewing of the T-helper cell response from T H 2 to T H 1. 116 It is tempting to speculate that luminal exorphins, some of which may derive from intestinal micro¯ora, may, under normal circumstances, play an ecological role by participating in the maintenance of immunological tolerance within the mucosal immune system.
CONCLUSIONS
The biological plausibility that exogenous, gut-derived neurotoxins can enter the systemic circulation and, by operating during a critical window of vulnerability, damage the developing central nervous system and cause autism is widely accepted; sodium valproate and thalidomide taken orally by the mother during pregnancy can cause autism in the offspring; 117±120 the route to the foetal brain involves the mother's intestine. Could exogenous neurotoxic opioid peptides exert similar effects? Certainly, pharmacological modulation of endogenous opioid chemistry can have profound and reproducible effects upon neural development and behaviour; Sandman et al. have suggested that, in the pathogenesis of autism, b-endorphin may act as a natural teratogen. 121 Exogenous opioids may act similarly through direct and indirect mechanisms. The diet is one source of abundant exogenous opioids (and other potential neurotoxins) that, in the presence of intestinal mucosal pathology, may be inadequately degraded. Through a combination of altered epithelial permeability and mass action, these peptides may enter the systemic circulation in excess, and are detectable in the urine of children with autism. Hepatic encephalopathy, where an important role for aberrant opioid chemistry is becoming increasingly apparent, provides a prototypic model of gut±brain interaction that may render analogous pathological and therapeutic insights for those children with autism and entero-colonic pathology. The various concepts explored in this review are capable of generating an abundance of hypotheses, most of which are testable in clinical and laboratory settings. Initially, however, a comprehensive quantitative and qualitative characterization of opioid (endogenous and exogenous) pro®les is merited, in the blood, urine and cerebrospinal¯uid of phenotypically homogeneous groups of children with autism, both on and off exclusion diets, including matched controls.
